RxDoctor Payments Data

Janelle Auyang, PA

Medical · Williamsville, NYNPI 1508333733

Payments from drug & device makers

$6,933in general payments, 2019–2025

Across 505 payments — averaging $13.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AbbVie$1K
  • Regeneron Healthcare Solutions, Inc.$405
  • QOL Medical, LLC$363
  • Takeda Pharmaceuticals U.S.A., Inc.$344
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,66196%
  • Education$2724%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,933 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$44,689
Medicare patients
192
Services billed
801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast20$105,140
Tacrolimus79$16,951
Fluorouracil87$5,586
Ketoconazole159$4,713
Gentamicin Sulfate63$3,742
Clobetasol Propionate113$3,444
Clindamycin Phosphate103$3,229
Betamethasone Dipropionate45$2,809
Metronidazole49$2,450
Triamcinolone Acetonide155$2,166
Ivermectin11$1,820
CiclopiroxCiclopirox Olamine60$1,471
Levocetirizine Dihydrochloride213$1,463
Doxycycline Hyclate61$995
Ciclopirox40$934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$152$105,14020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,395 medical providers in New York.

Other medical in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →